Skip to main content

Table 3 Survival data of PO-HPD patients and patients with stage IV pancreatic cancer

From: Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study

 

PO-HPD

(n = 101)

Stage IV

(n = 1733)

Median total survival (m, IQR)

12.5 (10.7–14.4)

10.7 (4.0–12.0)

6-month survival

76.8%

53.4%

12-month survival

36.6%

24.3%

2-year survival

5.9%

7.1%

  1. PO-HPD Postoperative hyper-progression disease, IQR Inter-quarter range
  2. Total survival was counted from the date diagnosed as pancreatic cancer to the date of death or last follow-up
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us